Gland Pharma and Neuland Labs Form Partnership to Expand Sterile API Manufacturing
Gland Pharma and Neuland Laboratories have entered a long-term CDMO partnership to establish a sterile manufacturing suite at Gland Pharma's Visakhapatnam facility. This suite, designed to add around 1,400 kg of annual capacity, will support the growing demand for sterile active pharmaceutical ingredients (APIs) used in microparticle depot products and other complex sterile APIs. The collaboration combines Neuland's complex API development expertise with Gland Pharma's sterile manufacturing capabilities, adhering to cGMP, US FDA, and EU standards to offer integrated development, scale-up, regulatory support, and commercial manufacturing services.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 34/100.
Outlets measured: news18, thehindu, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–74/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 5 Aug, 01:10 pm. Other outlets followed.